This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu (CORTIFLU)

This study has been terminated.
(the H1N1 pandemic is now over, and fewer cases than expected were observed)
Sponsor:
Collaborator:
Assistance Publique - Hôpitaux de Paris
Information provided by (Responsible Party):
Djillali Annane, University of Versailles
ClinicalTrials.gov Identifier:
NCT01014364
First received: November 16, 2009
Last updated: December 17, 2014
Last verified: December 2014
History of Changes
November 16, 2009
December 17, 2014
March 2010
June 2011   (Final data collection date for primary outcome measure)
in hospital all cause morality [ Time Frame: hospital discharge up to 90 days ]
in hospital all cause morality [ Time Frame: hospital discharge ]
Complete list of historical versions of study NCT01014364 on ClinicalTrials.gov Archive Site
  • 28 day mortality [ Time Frame: 28 day ]
  • 90 day all cause mortality [ Time Frame: 90 day ]
  • 6 month all cause mortality [ Time Frame: 180 days ]
  • mechanical ventilation free days [ Time Frame: hospital discharge up to 90 days ]
  • intensive care unit free days [ Time Frame: hospital discharge up to 90 days ]
  • proportion of patients with secondary infections [ Time Frame: hospital discharge up to 90 days ]
  • proportion of patients who require ECMO [ Time Frame: hospital discharge up to 90 days ]
  • respiratory function and health status [ Time Frame: 180 days ]
  • 28 day mortality [ Time Frame: 28 day ]
  • 90 day all cause mortality [ Time Frame: 90 day ]
  • 6 month all cause mortality [ Time Frame: 180 days ]
  • mechanical ventilation free days [ Time Frame: hospital discharge ]
  • intensive care unit free days [ Time Frame: hospital discharge ]
  • proportion of patients with secondary infections [ Time Frame: hospital discharge ]
  • proportion of patients who require ECMO [ Time Frame: hospital discharge ]
  • respiratory function and health status [ Time Frame: 180 days ]
Not Provided
Not Provided
 
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
Phase III Study of Hydrocortisone in Patients With Severe H1N1 Related Pneumonia
The H1N1 flu pandemic is one of the major infectious threat of the past half century. it is rapidly progressing worldwide and a substantial number of patients get severe H1N1 related pneumonia that requires mechanical ventilation and admission to the intensive care unit. The acute respiratory distress syndrome is associated with a substantial mortality and morbidity partly as a consequence of uncontrolled lung and systemic inflammation. many physicians are trying to counteract this pro-inflammatory storm by the use of corticosteroids albeit these drugs may cause super infection or metabolic disorders. Thus, there is a need for a randomized double blind, placebo controlled trial to define the benefit to risk ratio of corticosteroids in this patient.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Pneumonia, Viral
  • Influenza in Humans
  • Drug: hydrocortisone
    50mg intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
    Other Name: hydrocortisone acetate
  • Drug: isotonic saline
    intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
    Other Name: normal saline
  • Experimental: Corticosteroids
    Hydrocortisone
    Intervention: Drug: hydrocortisone
  • Placebo Comparator: Control
    isotonic saline
    Intervention: Drug: isotonic saline
Annane D, Antona M, Lehmann B, Kedzia C, Chevret S; CORTIFLU Investigators; CRICs; AZUREA; REVA/SRLF networks. Designing and conducting a randomized trial for pandemic critical illness: the 2009 H1N1 influenza pandemic. Intensive Care Med. 2012 Jan;38(1):29-39. doi: 10.1007/s00134-011-2409-8. Epub 2011 Nov 26.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
40
December 2011
June 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • age above 15 years old
  • admitted to intensive care unit
  • proven or strong suspicion of H1N1 Influenza infection
  • diffuse pneumonia (for less than 96 hours)
  • need for non invasive or invasive mechanical ventilation

Exclusion Criteria:

  • pregnancy
  • an age of 15 or less
  • rapidly fatal underlying disease with a life expectancy of one month or less
  • more than 3 organ dysfunction upon admission
  • previous treatment with corticosteroids (ie prednisone 30 mg per day or more, or equivalent, for at least one month)
  • formal indication for corticosteroids (eg Addison disease, status asthmaticus)
  • already on corticosteroids for 2 days or more in the management of the current episode
  • acute lung injury not related to viral pneumonia
  • presence of H1N1 related acute myocarditis or encephalitis
  • receiving antiviral treatment for more than 5 days
Sexes Eligible for Study: All
15 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT01014364
PCR09006
Yes
Not Provided
Not Provided
Not Provided
Djillali Annane, University of Versailles
University of Versailles
Assistance Publique - Hôpitaux de Paris
Study Chair: Djillali Annane, MD,PhD AP--HP and University of Versailles SQY
Principal Investigator: Christian Brun Buisson, MD AP-HP and Paris XII University
Principal Investigator: Charles Mayaud AP-HP and University of Paris VII
Principal Investigator: Bernard Régnier AP-HP and Paris VII University
Principal Investigator: Christian Perronne AP-HP and University of Versailles SQY
University of Versailles
December 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP